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Abstract: 
Background & Aims: A subset of patients with hepatocellular carcinoma 
(HCC) beyond Milan criteria might obtain acceptable survival outcomes after 
liver transplantation. Living donor liver transplantation (LDLT) has emerged as a 
feasible alternative to overcome the paucity of donors. 
Methods: In 2001 we started a protocol for LDLT in Child A-B patients with 
HCC fulfilling a set of criteria – the BCLC expanded criteria- that expanded the 
conventional indications of transplantation: 1 tumor < 7cm, 5 tumors < 3cm, 3 
tumors < 5cm without macrovascular invasion or down-staging to Milan after 
loco-regional therapies.  
Results: We present a prospective cohort of 22 patients with BCLC extended 
indications based on size/number (17) or down-staging (5) treated with LDLT 
between 2001 and 2014. Characteristics of the patients were as follows: median 
age: 57yr old; males/female: 20/2, Child-Pugh A/B: 16/6, AFP <100ng/mL: 21. 
Twelve patients received neo-adjuvant loco-regional therapies. At the time of 
transplantation, 12 patients had HCC staging beyond Milan criteria and 10 
within. Pathological reports showed that 50% exceeded BCLC expanded 
criteria. Perioperative mortality was 0%. After a median follow up of 81 months,  
the 1-, 3-, 5- and 10-year survival was 95.5%, 86.4%, 80.2% and 66.8%, 
respectively. Overall, seven patients recurred (range 9-108 mo), and the 5-y 
and 10-yr actuarial recurrence rate was of 23.8% and 44,4%, respectively.  
Conclusion: A proper selection of candidates for extended indications of living 
donor liver transplantation for HCC patients provide survival outcomes 
comparable to those obtained within the Milan criteria, but these results needs 
confirmation. 
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INTRODUCTION 
Liver cancer is the second leading cause of cancer-related death globally and 
has an incidence of 850,000 new cases per year. Hepatocellular carcinoma 
(HCC) represents approximately 90% of all cases of primary liver cancer(1,2). 
The prognosis of patients affected by HCC depends on the tumor stage and the 
degree of liver function impairment(2). Today, as a result of screening 
programs, about 30-40% of these patients can receive treatments with curative 
intent, including liver resection, liver transplantation and percutaneous ablation, 
with a 5-year survival between 50-75%(1–5).  
Liver transplantation offers the possibility of removal of both HCC tumor and 
preneoplastic underlying disease and may be applied to patients with advanced 
liver failure. When strict criteria are applied (the so-called Milan criteria(6) – 1 
tumor ≤ 5cm or 3 tumors ≤ 3 cm), the 5-year overall survival reaches 70%(7,8). 
Today, these criteria are included in the Barcelona Clinic Liver Cancer (BCLC) 
staging system for HCC(3–5). 
Selected patients with HCC beyond the Milan criteria may still obtain acceptable 
rates of survival after liver transplantation, as pointed by several studies(9–13). 
These patients generally belong to an intermediate group between the ones 
with excellent prognosis after liver transplantation (Milan-in patients) and those 
with indicators of rapid disease progression (macroscopic vascular invasion, 
diffuse HCC or extrahepatic disease). Despite some efforts to expand 
indications of transplant for HCC patients beyond Milan criteria –based on 
tumor size and number of nodules or successful down-staging after 
preoperative therapies(9–13) - clinical practice guidelines have not adopted 
such extended criteria and the vast majority of transplant centers are still 
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excluding this type of patients from liver transplantation with cadaveric 
grafts(3,4,14).   
The 2010 Consensus Conference on liver transplantation for HCC recommends 
living donor liver transplantation (LDLT) as an ethically acceptable alternative 
for patients with expected 5 year survival comparable to that of patients 
receiving a cadaveric graft, although the strength of recommendation is weak, 
because of the different approaches between transplant centers(14). From this 
point of view, LDLT represents an alternative option for patients with HCC 
beyond the Milan criteria, because it offers them a curative treatment without 
affecting the pool of donors for patients enlisted for deceased liver 
transplantation. 
In 2000, our group began a local program of LDLT, and in March 2001 it was 
expanded following a specific protocol(15) allowing enlisting HCC patients 
beyond Milan criteria as per Table 1. The main objective of this pilot study was 
to assess the survival and recurrence rates after LDLT in this type of patients. 
We report herein the results of a pilot prospective study including 22 HCC 
patients with extended indications treated by LDLT and followed for a long- term 
period. 
PATIENTS AND METHODS 
Between March 2000 and December 2014, 97 patients were effectively 
transplanted in the LDLT program of our Liver Transplantation Unit following a 
previously published protocol(16). Indication for transplantation was based upon 
HCC diagnosis in 39 (40.6%) of these patients, 22 of them being accepted 
according to expanded HCC criteria applied at our institution since March 2001 
(Table 1)(15). These 22 patients represent our study population.  
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Patients  
Recipients and Donor Selection. The complete preoperative study and the 
donation planning were  done according to the Spanish Law of Organ Donation, 
as previously described(16). Detailed explanations related to the procedure, its 
complexity and possible complications is a critical part of the process for both 
the donor and the recipient(17). Inclusion criteria of the recipients were as 
follows: diagnosis of HCC according to EASL and AASLD guidelines(3,4,18), 
age between 18 and 70 years, BCLC expanded criteria for LDLT (see Table 1), 
ECOG performance status 0 and Child-Pugh A or B class. Preoperative HCC 
staging work–up included four-phase abdominal CT scan or MRI, thorax X ray 
and bone scintigraphy. Size of the main nodule was established according to 
either CT scan or MRI, whereas additional nodules would require 2 coincidental 
imaging techniques if size between 1-2 cm, and one imaging technique if size > 
2cm, showing the radiological hallmark of HCC. AFP plasma levels > 1000 
ng/mL required further work-up to discard advanced disease (laparoscopic 
ultrasound and body CT scan). Status of vascular invasion was defined by 
Doppler US and/or MRI. Doubts regarding the nature of a portal thrombosis 
were ruled out by biopsy studies. Recipient exclusion criteria were: patients 
older than 70 years, single tumor larger than 7 cm or smaller but with satellites 
(defined as any HCC < 2m within a 2cm ring around the main nodule), 
multinodular tumor beyond inclusion criteria, diffuse HCC, neoplastic vascular 
invasion of any vessel, lymph node involvement or extrahepatic tumor disease, 
Child-Pugh C class or ECOG performance status > 0. In case of recipients aged 
between 66-70 yrs old, additional cardiovascular (normal cardiac stress test), 
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respiratory (low risk of complications by pulmonary function testing) and renal 
test (normal renal function) were conducted. Recipient evaluation includes the 
same parameters as in conventional liver transplantation. Donor selection 
criteria included age between 18 and 55 years, ABO group compatibility with 
the recipient, healthy individuals with graft to body weight ratio (GBWR) higher 
than 0.8 and normal psychological work-up. All donors signed informed consent 
in front of a judge according with the law. Work-up for donors has been reported 
in previous studies of our group(16,19). A key aspect of this work-up is the 
analysis of graft vascular and biliary distribution, and graft volume using CT 
scan and MRI-angiography, which can anticipate the complexity of the surgery 
and eventually even contraindicate the procedure(19,20). Donors with liver 
steatosis by imaging techniques and normal blood analysis, were only 
considered in case that liver biopsy demonstrates <20% of liver steatosis.    
Feasibility. The protocol execution contained two parts: the feasibility part (9 
cases) and the complete final pilot study (up to 22 cases). The feasibility run-in 
part involved the evaluation of the first 9 LDLT cases, and results have been 
previously communicated(21). In this part we assessed whether the protocol 
was feasible, the number of potential cases emerging out of the total HCC 
cases visited, the number of donors per candidate recipient, and the reasons for 
accepting/rejecting the candidate. The study team estimated that the results 
obtained at this cut-off point were adequate, and thus agreed proceeding to the 
completion the study with an initial target sample size of ~20 cases. For the 
purpose of the current report, the recruitment ends at December 2014, and the 
follow-up expands to February 2017.  
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Patient characteristics. Baseline characteristics of the patients before LDLT are 
depicted in Table 2. For every recipient, data regarding age, sex, etiology and 
preoperative stage of hepatic disease, treatment performed before LDLT (as 
neo-adjuvant or down-staging therapy), pre and post-transplantation liver 
function, alpha fetoprotein (AFP) levels before and after LDLT, preoperative 
radiological stage, explant histological result, number and type of intra and 
postoperative complications according to the Clavien-Dindo scale(22), intensive 
care unit (ICU) and hospital stay, type of immunosuppression, follow-up, 
recurrence and death were prospectively recorded in a database and analyzed.  
Methods 
Loco-regional therapies previous to LDLT. In 12 patients (54.5%) loco-regional 
therapies were performed (11 cases treated with TACE and one case with PEI) 
(Figure 2). In five of these cases, down-staging (i.e. remaining within Milan 
criteria in two consecutive radiological assessments) allowed inclusion in the 
expanded criteria used at our center. In all the remaining cases, patients were 
already meeting one of the “size and/or number” expanded criteria. 
Surgical intervention and postoperative period. The LDLT procedure followed 
the protocol of our Liver Transplantation Unit, as previously 
described(16,19,20). All 22 transplants were performed using the right liver 
lobe. Surgical procedure details, intraoperative incidences, ICU and hospital 
stay, postoperative complications and immunosuppression therapy used were 
also recorded. Postoperative immunsupression regimens followed a 
standardized protocol. In principle, the immediate post-transplant 
immunosupression treatment includes methylprednisolone in descending 
dosage along with calcineurin inhibitors (tacrolimus, but cyclosporine in cases of 
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pre-transplant diabetes). Mycophenolate mofetil is generally used until reaching 
therapeutic levels of calcineurin inhibitors. mTOR treatments, such as 
everolimus, were used in 4 cases. 
Follow up and assessment of recurrence. After being discharged, all patients 
were followed monthly in the outpatient clinic until 90 days from LDLT, every 
other month during the 1st year after LDLT, and every three months until two 
years from the transplantation. In addition to conventional clinical parameters 
(symptoms related to the tumor or hepatic decompensation), radiological 
explorations (US, CT or MRI) and liver function assessment were performed in 
each outpatient visit during the first two years. Follow-up beyond this time 
period with blood test and radiological imaging was based upon clinical criteria.  
Pre-LDLT radiological exam and histological explant analysis. Median time 
between donor and recipient evaluation (including treatment/down-staging) and 
transplant was of 4,5 months. Assessment of pre-LDLT radiological exam 
included number, site and maximum diameter of tumor nodules, viable tumors 
after neo-adjuvant therapy, and satellites nodules. The pathological report of the 
explanted liver includes the following information: description of number, 
location and maximum diameter of all tumor nodules, differentiation degree, 
presence of micro or macrovascular invasion, and satellite nodules.  
Statistical Analysis.  
Epidemiological and analytical quantitative data are expressed as mean ± SD. 
Follow-up length, overall survival and time to recurrence are expressed as 
median (range). Probability curves of patient and graft survival were calculated 
according to the Kaplan-Meier method and compared by the Mantel-Cox test. 
Differences between qualitative variables were assessed by the Fischer exact 
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test; differences between quantitative variables were analyzed by t-test. All the 
calculations were performed by using the IBM© SPSS Statistics version 22 
package.  
RESULTS 
Feasibility. The feasibility run-in part of the study was conducted between 
March 2001 and December 2002 (Figure 1), as previously reported(21). During 
this time period 381 patients with HCC were visited in our BCLC program, 
among which 142 (37%) received either resection (22 cases), orthotopic liver 
transplantation (36 cases) or percutaneous ablation (84 cases). A total of 34 
patients (9%) were considered for the specific protocol for LDLT as per BCLC 
expanded criteria. Finally, 205 patients received loco-regional or symptomatic 
treatment according to guidelines(18). No systemic therapy with sorafenib was 
available at that time as standard of care, since benefits of this therapy were 
reported afterwards(23). 
Among 34 patients evaluated for LDLT, 13 did not find/required any donor 
candidate (recipient refuse the procedure: 10; HCC progression while 
evaluation: 2; Recipient unable to identify a donor: 1), whereas 21 provided 57 
potential donors. Among these cases, 12 recipients had an inadequate donor 
[20 donors evaluated: blood ABO incompatibility (5), liver steatosis (6) or 
medical contraindications (9)]. Finally, 9 patients received a LDLT during this 
run-in period, representing ~25% of the 34 receptors evaluated, and 2,6% of the 
total HCC patients visited during this time period. All these data were 
considered acceptable for the feasibility/run-in period, and thus the protocol was 
approved for completion, with a final recruitment number of 22 cases. 
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Loco-regional treatment and tumor stage prior to LDLT. Out of the 22 final 
candidates with BCLC extended indications, 17 patients were included in the 
protocol due to extended “size & number” criteria, and 5 due to downstaging to 
Milan criteria from any previous size (Figure 2). All patients achieving 
downstaging to Milan criteria were treated with TACE (overall, median time on 
downstaging was 134 days). Among 17 additional patients meeting “size & 
number” criteria, 7 received treatment (6 with TACE and 1 with PEI) as a bridge 
therapy while waiting to complete pre-transplant evaluation in patients with long 
evaluation times. 
Thus, overall 12 patients were ultimately treated with neo-adjuvant loco-regional 
treatment while waiting for LDLT or to achieve downstaging.  Out of the 12 
cases treated, 5 (22.7%) achieved complete response, six (27.3%) partial 
responses and one case showed stable disease. Four patients who responded 
to treatment presented hepatic recurrence before LDLT. Median time between 
last radiological exploration (MRI in 19 cases, and CT scan in 3) and LDLT was 
59 days. At the last imaging technique prior LDLT, 10 out of 22 patients (45.5%) 
presented a tumor stage inside Milan criteria. 
Surgical data. Mean GBWR estimated before surgery was of 1.26 ± 0.32, while 
the actual GBWR calculated with the graft lobe weight was of 1.09 ± 0.27. Total 
surgery time between donor and recipient intervention was of 417 ± 83 minutes. 
Mean final portal and arterial flow were of 1552 ± 520 ml and 189 ± 101 ml 
respectively. Eleven patients required red blood cells transfusion during surgery 
(mean of 3.9 ± 3.1 RBC concentrates / transfused patient), 14 plasma 
transfusion (mean of 1714 ± 738 ml / transfused patient) and 3 platelets 
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transfusion (mean of 6.4 ± 5.5 platelet units / transfused patient). No patient 
developed small-for-size syndrome.  
Explant histological results. Explant histological characteristics are depicted 
in Table 3. Median size of the main nodule was 32,4 mm, 19 patients presented 
multinodular disease, 10 (45.5%) microvascular invasion and 9 (40%) satellites. 
In terms of pathological tumor staging, 4 patients (18.2%) were inside Milan 
criteria, 7 patients (32%) were beyond Milan criteria but inside our BCLC 
expanded criteria and 11 patients (50%) were beyond these criteria. Overall, the 
number of tumors in the histological exam was higher than in the last 
radiological imaging prior LDLT (5 cases in explant vs 3 in MRI/CT before 
LDLT).  
Postoperative period and follow-up. Perioperative complications for donors 
and recipients are summarized in Table 4. Median intensive care unit stay and 
total hospital stay for receptors was 6+4 days (3-24) and 27+22 days (9-101), 
respectively. Medical complications for the recipient occurred in 12 cases (54%) 
and surgical complications in 16 cases (72%). Among the latter, biliary leak (13 
cases) resulting in surgical treatment in 8 cases was the most notorious.  
Perioperative mortality was 0%. Regarding long-term complications, 9 patients 
presented HCV-induced cirrhosis and there was 1 case of chronic rejection. No 
indication for retransplantation was made.  
From the donor stand point, 5 patients (22%) presented perioperative 
complications, one of which was grade IIIb Clavien-Dindo scale(22) (bile leak 
which required surgical reintervention).  
Overall Survival: After a median follow-up of 81 months (range 7-188), 8 
patients died, four of which due to HCC recurrence (Table 5). Actuarial 
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provability of survival at 1, 3, 5 and 10 years was of 95.5%, 86.4%, 80.2% and 
66.8%, respectively (Figure 3).  
Recurrence rates. At the end of follow-up 7 patients recurred, 2 only in the liver 
(91 and 62 months after LDLT), 1 in liver and bone (at 9 months), 1 in form of 
liver tumor and peritoneal carcinomatosis (at 58 months), 1 in the liver and 
mediastinal lymph nodes (at 57 months), 1 in the liver and adrenal gland (54 
months), and 1 as bilateral adrenal gland (9 years after LDLT). Four patients 
died within the first year after presenting the recurrence, whereas three patients 
(liver recurrence with mediastinal lymph nodes at 57 months and with adrenal 
gland metastasis at 54 months respectively  and adrenal gland metastases) are 
still alive. All seven patients were initially HCV positive and five of them had 
cirrhosis recurrence confirmed by histology. Explant histology showed that six of 
the patients were outside BCLC extended criteria, with microvascular invasion 
in 5 cases and satellites in 3. One of the patients was inside BCLC expanded 
criteria but presented microvascular invasion and satellites. No relationship was 
found between the recurrence and the type of immunosuppression. Overall, the 
actuarial probability of recurrence at 5 and 10 years was of 23.8 % and of 
44.4% respectively (Figure 4). One of recurrences was detected 1 year after the 
patient had received HCV direct-acting antivirals. Two patients were treated 
with sorafenib, and four are currently dead due to tumor progression.  
Prognostic Factors. Better overall survival was observed for patients that were 
within the Milan criteria (n=10) in the last radiological exploration before LDLT 
when compared with patients that were beyond these criteria (n=12) at the 
same time period (5-y and 10-yr survival 90% and 90% vs. 70% and 52.1%, 
respectively; p=0.046) (Figure 5). Survival was not significantly influenced by 
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any other variable related with preoperative stage, histological explant analysis 
or intra and postoperative complications.   
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DISCUSSION 
The incidence of HCC is steadily growing globally, but just around 30-40% of 
those patients are amenable for potential curative therapies(1–5). Benefits from 
OLT are clearly achieved when applying the Milan criteria, which have been 
widely adopted by Clinical Practice guidelines of management of HCC(3,4), 
guidelines of liver transplantation(14) and by the US United Network of Organ 
Sharing. Recent meta-analysis of patients undergoing OLT for HCC within Milan 
criteria confirm that a 5-yr and 10-yr survival rates of 70% and 50%, 
respectively, are consistently reported(7). Nonetheless, the applicability of OLT 
in those patients is limited due to the shortage of donors, a problem that has not 
been solved during the past two decades. As a consequence, a proportion of 
patients dies on the waiting list or is not even considered for OLT. In parallel, 
different studies have shown 5-yr survival rates > 50% in selected patients with 
HCC beyond Milan criteria submitted to liver transplantation when compared to 
their counterparts within Milan criteria(9–13), posing the question of whether 
Milan criteria are too strict for nowadays radiological standards compared to 
those of 1996(6).  
LDLT can be a thorough alternative to OLT in referral centers because it is not 
limited to the shortage of donors(14,24). This strategy appears appealing since 
there is no prejudice for other candidates to OLT in the waiting list, mostly 
cirrhotic patients with end-stage disease. Of note, guidelines have emphasized 
that from the ethical perspective the concept of double equipoise (meaning a 
balance between the risk of a healthy donor and the benefit for the HCC patient) 
should be considered(14). The risk of mortality for a donor of the right lobe is 
reported to be around 0.17%(25). 
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LDLT has been proposed in two areas: for patients on the waiting list of OLT 
and for those exceeding Milan criteria. A recent meta-analysis has pointed out 
that outcomes for LDLT and OLT are similar in terms of survival(26) when 
considering Milan–in only patients. The most burning question, however, and 
the one addressed in the current study, is whether LDLT is safe and efficacious 
in patients exceeding Milan criteria. Such patients are mostly categorized as 
BCLC stage A or B and are treated with chemoembolization in most instances, 
achieving median survival rates ranging from 30-45 months(3,4). In some 
series, however, median survival ~50 months has reported in outstanding 
candidates(27), which provide a framework for comparing the outcomes 
reported herein with LDLT. So far, expansion of criteria has been mostly based 
upon tumor size and number, in the case of USCF(12) and up-to seven 
criteria(9), tumor volume(28) or even molecular characteristics based upon 
gene expression(29). Finally, AFP has also been incorporated into the selection 
of candidates in France(30) and Canada (31), where patients with AFP > 1,000 
ng/dL are excluded from transplant due to poor outcome.  
We herein present the outcome data of a pilot prospective cohort study with 
pre-defined modest expansion criteria previously reported(15). These criteria 
are based upon size and number (single < 7cm, 3 nodules < 5 cm, 5 nodules < 
3 cm), or tumor behavior (down-staging to Milan after loco-regional therapies), 
absence of tumor-related symptoms (ECOG 0) and well-preserved liver function 
(Child A or B). Almost all patients were transplanted with AFP < 100 ng/mL, and 
there were no patients with AFP >1,000 ng/mL. Results of this pilot study reveal 
potential implications on the future management of HCC for a small population 
of patients with LDLT due to the survival outcome achieved.  
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Survival data was remarkable. Overall survival at 5 and 10-yr was of 80% and 
66.8%, after a median follow up of around 81 mo. These figures compare well 
with those reported for deceased liver donor transplantation(7), which is the 
master framework for any comparison(14). Even when further analyzing 
outcomes in patients maintaining beyond Milan criteria in the last radiological 
exam before LDLT –despite the small sample size (12 patients) - the 5 and 10-
yr probability of survival is still around 70% and 50%, respectively. Of note, the 
current European report of liver transplantation for HCC including ~19,000 
cases –within/beyond Milan criteria- reports a 10-yr survival rate of 50%(32). 
Survival also outperforms the outstanding median of ~50 months reported after 
TACE in selected patients(27). Thus, overall the survival figures fit well with the 
pre-planned expectations, and the accepted outcomes for proposing LDLT in 
HCC.  
On the other hand, the actuarial probability of recurrence at 5 and 10 years was 
of 23.8 % and of 44.4%, respectively. As expected, the majority of the patients 
showed a pathological staging beyond BCLC extension criteria, mostly as a 
result of additional small nodules not detected in pre-operative imaging staging. 
In fact, 6 out of 7 cases recurrences occurred in patients with pathological 
staging beyond BCLC extension criteria. While 5-yr recurrence rates are slightly 
higher than the ones reported for patients within Milan (23.8%), 10-yr recurrent 
data requires some analysis. The latter figure is difficult to interpret since almost 
no data has been reported in terms of 10-yr recurrence rate after liver 
transplantation. Interestingly, one of the late recurrences was detected after 1 
year of HCV treatment with direct antiviral agents, which adds further data in the 
controversy on the potential increase of HCC recurrence with these agents (33). 
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In terms of potential chemopreventive intervention, a recent randomized trial 
failed to demonstrated benefits in terms of recurrence-free survival for sirolimus-
based immunosuppression treatment in preventing recurrence after HCC 
transplant(34). Thus, so far only candidate selection might diminish this 
figure(9). 
Overall, the results are positive, but certainly need to be validated prior being 
considered for consensus criteria. In addition, they should be carefully 
interpreted. First, applicability of LDLT in our environment was low, since we 
were able to effectively operate only 22 patients within a 14-yr period. In fact, 
applicability of LDLT was explored in the first run-in part of the study(21). Out of 
a total of 381 patients with HCC visited during a twenty-two months period, only 
34 were potential candidates for LDLT (9%), and among those only 9 were 
effectively transplanted, representing 25% of those evaluated and around 2,6% 
of the total HCC population of a center of reference. Second, considering the 
concept of double equipoise, we need to emphasize that 5 donors (22%) 
presented post-operative complications, one of which requiring surgical re-
intervention. This complication rate is below the previously reported on a large 
series of cases(35). Recipient complications were within the expected range 
reported, with no perioperative mortality. Third, a proportion of patients with 
extended indications actually presented down-staging, meaning a pre-operative 
staging prior transplant of Milan-in after loco-regional therapy(14,34). This 
treatment was adopted in order to achieve down-staging to Milan (median of 
134 days of down-staging before LDLT) as the primary inclusion criteria in five 
cases or because they were treated while waiting for completing the pre-
operative evaluation, which as a whole lasted 4,5 months. These considerations 
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should be taken into account for tempering the potential excitement when 
analyzing the raw outcome obtained in the global context of LDLT(36,37). Of 
note, the recently reported AASLD guidelines suggest, based on low evidence, 
that patients beyond Milan criteria should be considered for transplantation after 
successful down-staging into the Milan criteria (38). 
In conclusion, our study adds a valuable piece of information in the context of 
the effectiveness of LDLT for extended indications of HCC. This prospective 
study report acceptable survival outcomes comparable to those obtained within 
the Milan criteria, thus supporting a minor expansion in the selection criteria of 
HCC candidates for LDLT. Despite that the 10-yr recurrence is high, the 
outcome is counterbalanced by the long-term transplant benefit achieved (39). 
We propose, therefore, pursuing these extended criteria in other centers of 
excellence, since these results need further prospective confirmation before 
being adopted by clinical practice guidelines. 
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TABLES 
 
Table 1. BCLC Expanded Criteria Proposed for Living Donor Liver Transplantation. 
Size and number criteria 
 Single HCC 5-7 cm 
 Multinodular HCC: up to 3 nodules ≤ 5 cm or 5 nodules ≤ 3 cm 
Down-staging criteria 
 Downstaging: Partial response to any tumor stage by using loco-
regional therapies that has been confirmed by 2 radiological 
techniques (CT scan or MRI) separated at least 1 month 
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Table 2. Baseline Characteristics of the 22 patients before LDLT 
Epidemiological  and clinical data 
 Mean age (years) 57,3 ±6,0 
 Sex (M/F) (%) 20 (90.9%) / 2 (9.1%) 
 Etiology of hepatic cirrhosis  
  Hepatitis C virus (%) 14 (63.6%) 
  Hepatitis B virus (%) 2 (9.1%) 
  Alcohol (%) 4 (18.2%) 
  Hepatitis C virus + alcohol (%) 2 (9.1%) 
 Expanded criteria used as indication for LDLT (%) 
  1 tumor 5-7 cm 3 (13.6%) 
  3 tumors < 5 cm 7 (31.8%) 
  5 tumors < 3 cm 7 (31.8%) 
  Down-staging to Milan criteria 5 (22.7%) 
 Previous descompensation  
  Encephalopathy (%) 0 (0%) 
  Variceal bleeding (%) 0 (0%) 
  Ascites (%) 7 (31.8%) 
Analytical data  
 Serum bilirubin (mg/dL) 1,6 ± 0,9 
 Prothrombin activity (%) 72,0 ± 12,3 
 Serum albumin (g/L) 34,0 ± 4,8 
 ALT (IU/L) 81,5 ± 72,0 
 AST (IU/L) 84,4 ± 61,8 
 Gamma-glutamyltranspeptidase (IU/L) 108,2 ± 59,7 
 Alkaline phosphatase (IU/L) 299,0 ± 111 
 Blood urea nitrogen (mg/dL) 15 ± 3,7 
 Creatinine (mg/dL) 0,9 ± 0,2 
 Alpha-fetoprotein (<10/10-100/>100 ng/mL) 17,2 ± 247(13/8/1) 
 Child-Pugh score (A/B/C) 6 ± 1,1(16/6/0) 
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Table 3. Explant histological results after LDLT and imaging-pathological 
correlation  
Explant histological results  
Size of main nodule (mm)  32,4±1,7 
Multinodular (%)  19 (86,4%) 
 2 nodules 7 (36,8%) 
 3-4 nodules 3 (15,8%) 
 >4 nodules 9 (56,3%) 
Historical grade (complete necrosis*/I/II/III) 1/5/11/5 
Microvascular invasion (%) 10 (45,5%) 
Satellite nodules (%) 9 (40,9%) 
Pathological assessment of extension  
 Beyond Milan (%) 18 (81,8%) 
 Beyond San Francisco (%) 16 (72,7%) 
 Beyond Up-to-7 (%) 13 (59,1%) 
Imaging-pathological correlation** 
 Preoperative Histological result 
Number of tumors (median) 3 5 
Size of largest tumor (mm) 30,1±15,44 32,5±1,7 
Bilobular lesions 12 (54,5%) 15 (68,2%) 
Beyond Milan 12 (54,5%) 18 (81,8%) 
Beyond BCLC extended 0 11 (50%) 
 
* Complete necrosis at explant: 1CR. ** Median time of last CT/MRI prior to LDLT: 59 days (5-
151days);  
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Table 4. Recipient and donor perioperative complications 
 
Recipient preoperative complications 
ICU stay (days)  6,1±4,3 
Hospital stay (days)  27,7±22,6 
Perioperative mortality   0 
Medical complications  12 (54,5%) 
Respiratory complications  1 
Renal failure  2 
Infections   
 Bile/abcess/others 6/1/4 
Ascites  1 
Acute rejection  3 
Surgical complications  16 (72%) 
Biliary complications*   16 (72%) 
 Biliary leak 13 (31%) 
 Treatment (medical/surgery) 5/8 
 Biliary stenosis 9 (40%) 
 Treatment (surgery/I.R/ERCP) 3/5/1 
 
 
Donor characteristics and outcome  
Number of donors  22 
Mean age (years)  33,7 ±9,61 
Gender (M/F) (%)  15 (68%)/7 (31%) 
Radiological overestimation of lobe weight 13 (59,1%) 
Graft to body weight ratio (GBWR) (median, range) 0,86 (0,74-0,99) 
Hospital stay (days, range) 10,3 (6-35) 
Complications (%)  5 (22,7%) 
 Clavien-Dindo Classification (I/II/III) 2/2/1 
 Surgical reintervention 1 
 Long-term complications 0 
 
 
* 5 cases with both biliary leak and stenosis   
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Table 5. Deceased Patients: Median survival and Cause of Death 
 
Overall survival (months) Cause of death 
7 Hepatic artery thrombosis 
17 HCC recurrence 
25 Complications of HCV-cirrhosis 
60 HCC recurrence 
71 HCC recurrence 
94 HCC recurrence 
138 Complications of HCV-cirrhosis  
144 Complications of HCV-cirrhosis 
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FIGURE LEGENDS 
Figure 1. Feasibility study. Applicability of the LDLT for extended indications of 
HCC during the run-in period from March 2001 to December 2003  
Figure 2. Flow-chart of BCLC extended criteria indications and neo-adjuvant 
treatments applied prior LDLT 
Figure 3. Overall probability of survival of the 22 cirrhotic patients with BCLC 
extended indications for LDLT 
Figure 4. Actuarial probability of recurrence of the 22 cirrhotic patients with 
BCLC extended indications for LDLT 
Figure 5. Overall probability of survival according to last preoperative 
radiological exploration before LDLT 
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Figure 1. Feasibility study. Applicability of the LDLT for extended indications of HCC during the run-in period 
from March 2001 to December 2003  
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Figure 2. Flow-chart of BCLC extended criteria indications and neo-adjuvant treatments applied prior LDLT  
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Figure 3. Overall probability of survival of the 22 cirrhotic patients with BCLC extended indications for LDLT  
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Figure 4. Actuarial probability of recurrence of the 22 cirrhotic patients with BCLC extended indications for 
LDLT  
 
109x70mm (300 x 300 DPI)  
 
 
Page 36 of 36
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
  
 
 
Figure 5. Overall probability of survival according to last preoperative radiological exploration before LDLT.  
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